Altamira Therapeutics Ltd.
CYTO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | – | $0 | $306 | $64 |
| % Growth | – | -100% | 378.4% | – |
| Cost of Goods Sold | – | $0 | $1,444 | $2,241 |
| Gross Profit | – | $0 | -$1,138 | -$2,177 |
| % Margin | – | – | -372.4% | -3,407.3% |
| R&D Expenses | – | $3,035 | $14,622 | $3,203 |
| G&A Expenses | – | $3,092 | $3,377 | $3,576 |
| SG&A Expenses | – | $3,124 | $3,393 | $3,616 |
| Sales & Mktg Exp. | – | $15 | $16 | $40 |
| Other Operating Expenses | – | $0 | $113 | $30 |
| Operating Expenses | – | $6,540 | $18,014 | $6,871 |
| Operating Income | – | -$5,916 | -$18,014 | -$5,341 |
| % Margin | – | – | -5,894.3% | -8,361.4% |
| Other Income/Exp. Net | – | -$1,354 | -$646 | -$1,465 |
| Pre-Tax Income | – | -$7,270 | -$18,660 | -$6,806 |
| Tax Expense | – | $0 | -$10 | -$118 |
| Net Income | – | -$7,270 | -$26,528 | -$17,058 |
| % Margin | – | – | -8,680.2% | -26,703.1% |
| EPS | – | -14.81 | -582.58 | -515.11 |
| % Growth | – | 97.5% | -13.1% | – |
| EPS Diluted | – | -14.8 | -582.58 | -515.11 |
| Weighted Avg Shares Out | – | 491 | 46 | 33 |
| Weighted Avg Shares Out Dil | – | 491 | 46 | 33 |
| Supplemental Information | – | – | – | – |
| Interest Income | – | $730 | $114 | $27 |
| Interest Expense | – | $0 | $912 | $14 |
| Depreciation & Amortization | – | $5,916 | $119 | $76 |
| EBITDA | – | -$1,354 | -$17,636 | -$6,716 |
| % Margin | – | – | -5,770.6% | -10,512.8% |